Investment Rating - The report maintains a "Buy" rating for the stock, expecting a relative increase of over 20% compared to the benchmark index within six months [14]. Core Insights - The report highlights a global exclusive collaboration and licensing agreement between the company and F. Hoffmann-La Roche Ltd for the self-developed long-acting dual antibody QX031N, which targets TSLP and IL-33, potentially offering new treatment options for respiratory diseases like COPD and asthma [4][5]. - The agreement includes an upfront payment of $75 million and up to $995 million in milestone payments, reflecting the company's innovative capabilities and the market potential of the self-immune field [5][6]. - The company is recognized as a leader in domestic self-immune innovative drugs, with a mature pipeline entering a monetization phase and ongoing collaborations with global giants to expand market reach [8]. Company Overview - Latest closing price: HKD 25.26 - Total shares: 2.27 billion, with a market capitalization of HKD 57 billion - 52-week high/low: HKD 36.50 / HKD 5.95 - Debt-to-asset ratio: 80.94% - Price-to-earnings ratio: -27.3 [3]. Financial Projections - Expected revenue growth rates for 2025-2027 are 123%, 98%, and -33%, respectively, with EPS projected at -0.72, 0.48, and -0.72 CNY per share [8][10]. - The company anticipates a significant increase in operating income, with projections of HKD 354 million in 2025 and HKD 703 million in 2026, before a decline to HKD 473 million in 2027 [10][11].

Investment Rating - The report maintains a "Buy" rating for Anta Sports [5] Core Insights - Anta Sports' two main brands are performing steadily, while new brands continue to show high growth momentum [10] - The company has adjusted its revenue guidance for the Anta brand down to low single-digit growth due to a weak retail environment [10] - The multi-brand matrix of the company is seen as a rare resource with significant growth potential in the long term [10] Financial Data and Profit Forecast - Revenue projections for FY2023 to FY2027 are as follows: - FY2023: 623.6 billion RMB - FY2024: 708.3 billion RMB - FY2025E: 789.1 billion RMB - FY2026E: 858.1 billion RMB - FY2027E: 923.0 billion RMB - Net profit forecasts show a significant increase in FY2023 with 102.4 billion RMB, peaking at 159.2 billion RMB in FY2027 [9][20] - The gross margin is expected to improve slightly from 62.6% in FY2023 to 63.9% in FY2027 [9] Brand Performance - Anta and FILA brands showed low single-digit growth in Q3 2025, while other brands experienced a growth rate of 45-50% [10] - FILA's growth was impacted by delayed sales of autumn and winter products, but it is expected to maintain mid-single-digit growth for the year [10] - Other brands like Descente and Maia Active are showing strong growth, with Descente growing approximately 30% and Maia Active around 45% [10] Market Expansion - Anta Sports is expanding its overseas market with a target of reaching 1,000 stores in Southeast Asia within three years [10] - The company is focusing on brand building and market cultivation in strategic markets like Europe and the US [10] Profitability and Cost Management - The company emphasizes quality over quantity in its operations, maintaining a profit margin target of 20-25% for the Anta brand and around 25% for FILA [10] - The report indicates a slight decrease in profit forecasts for 2025-2027 due to the current weak retail environment [10]

Investment Rating - The report maintains a "Strong Buy" rating for Anta Sports [10][11]. Core Insights - Anta's main brand and FILA experienced low single-digit revenue growth in Q3 2025, while other brands saw a significant increase of 45%-50% [1][2]. - The company has adjusted its revenue guidance for the main brand to low single-digit growth for the year, while maintaining the forecast for other brands [10]. - The net profit forecast for 2025-2027 is adjusted to CNY 13.13 billion, CNY 14.77 billion, and CNY 16.46 billion, reflecting year-on-year growth rates of -16%, 12%, and 11% respectively [10]. Revenue Performance - Anta's main brand revenue showed low single-digit growth, with offline sales growing at a low single-digit rate and online sales at a higher single-digit rate [2]. - FILA's revenue also grew at a low single-digit rate, with online sales performing better [3]. - Other brands, including Descente, KOLON, and MAIA, reported substantial revenue growth rates of 30%, 70%, and 45% respectively [4][5][6]. Channel and Market Expansion - The company is exploring new retail formats and optimizing operational efficiency, including the expansion of outdoor segments and increasing coverage in key business districts [10]. - Anta has announced a three-year plan to open 1,000 stores in Southeast Asia and is expanding its presence in the U.S. and European markets [2]. Financial Projections - The projected total revenue for Anta Sports for 2025-2027 is CNY 78.06 billion, CNY 86.73 billion, and CNY 95.55 billion, with year-on-year growth rates of 10%, 11%, and 10% respectively [10][11]. - The earnings per share (EPS) for 2025 is estimated at CNY 4.64, with a price-to-earnings (PE) ratio of 16.5 for 2025 and 15 for 2026 [10][11]. Key Financial Metrics - The report indicates a return on equity (ROE) of 24.5% and a debt-to-asset ratio of 41% [6]. - The company's market capitalization is approximately CNY 235.9 billion [6].

Investment Rating - The report maintains a "Buy" rating for the company [8][6]. Core Views - The company has shown stable revenue growth driven by a solid wealth management performance and a recovery in credit demand in the UK [2][4]. - The net interest margin has stabilized and is expected to improve, leading to an upward revision of the net interest income guidance for 2025 from $42 billion to $43 billion [3][6]. - The company has increased its return on tangible equity (ROTE) guidance for 2025 to above 15% [1]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company's revenue increased by 4.8% year-on-year, and pre-tax profit rose by 4.5% [1]. - Non-interest income grew by 17.2% year-on-year, with wealth management business revenue increasing by 24.9% [4]. - The company attracted new investment assets worth $73 billion, with $42 billion coming from Asia [4]. Asset Quality - As of September, the non-performing loan (NPL) ratio was 2.50%, with a provision coverage ratio of 42% [5]. - The company expects credit costs to remain around 0.40% for 2025, with ongoing pressure in the Hong Kong commercial real estate sector [5]. Market Position and Valuation - The company is projected to achieve a target price of HKD 143.08 for 2026, corresponding to a price-to-book (PB) ratio of 1.50 times [6][8]. - The forecasted net profit for 2025-2027 is $22.86 billion, $23.49 billion, and $25.80 billion respectively, reflecting a growth of 6.9%, 3.3%, and 6.5% [6].

证券研究报告 港股通 中银香港 (2388 HK) 息差边际企稳增强经营韧性 华泰研究 季报点评 投资评级(维持): 买入 目标价(港币): 45.59 沈娟 研究员 SAC No. S0570514040002 SFC No. BPN843 贺雅亭 研究员 heyating@htsc.com +(86) 10 6321 1166 蒲葭依 研究员 SAC No. S0570525090001 SFC No. BVL774 李润凌* 联系人 SAC No. S0570123090022 lirunling@htsc.com +(86) 21 2897 2228 基本数据 | 收盘价 (港币 截至 10 月 28 日) | 38.48 | | --- | --- | | 市值 (港币百万) | 406,841 | | 6 个月平均日成交额 (港币百万) | 564.05 | | 52 周价格范围 (港币) | 23.75-39.24 | 股价走势图 (9) 9 27 44 62 Oct-24 Feb-25 Jun-25 Oct-25 (%) 中银香港 恒生指数 资料来源：S&P 经营预测指标与估值 | 会计年度 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4][6]. Core Insights - The company reported a net revenue of $1.523 billion for FY26Q1, representing a year-on-year increase of 6.1%, exceeding previous guidance [2][3]. - The company expects FY26Q2 net revenue to be between $1.132 billion and $1.163 billion, reflecting a year-on-year growth of 9%-12% [3]. - A three-year shareholder return plan has been initiated, with at least 50% of the previous fiscal year's net profit allocated for shareholder returns, including a cash dividend of $190 million and a $300 million share buyback plan [3]. Revenue and Profitability - The core business showed steady growth, with the overseas examination preparation business growing by 1.0% and domestic examination preparation for adults and college students increasing by 14.4% [2]. - Non-GAAP operating profit for FY26Q1 was $336 million, up 11.3% year-on-year, with an operating profit margin of 22.0%, an increase of 1.0 percentage points [3]. Financial Forecasts - The company has adjusted its net profit forecasts for FY26 to FY28 downwards by 8%, now projecting $442 million, $514 million, and $582 million respectively [4]. - Corresponding EPS for FY26 to FY28 is expected to be $0.28, $0.33, and $0.37, with current P/E ratios of 22x, 19x, and 16x respectively [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's Q3 2025 performance was slightly below expectations due to external factors such as weather, but the multi-brand strategy remains a cornerstone for long-term growth [4][6] - The company has shown stable growth in its main brand and FILA, while other brands have experienced significant growth, particularly in the outdoor segment [6] - The company is expanding its offline presence with new store formats, which are expected to drive future growth [6] - The multi-brand strategy is central to the company's operations, with recent acquisitions and partnerships aimed at enhancing market presence [6] - The establishment of a sneaker design program in collaboration with universities aims to foster innovation and talent in the industry [6] Financial Summary - Revenue projections for 2023 to 2027 are as follows: 62,356 million RMB (2023), 70,826 million RMB (2024), 78,015 million RMB (2025E), 86,289 million RMB (2026E), and 95,069 million RMB (2027E) [5][7] - The expected growth rates for revenue are 16.23% (2023), 13.58% (2024), 10.15% (2025E), 10.61% (2026E), and 10.17% (2027E) [5] - The projected net profit for 2025 is 13,443 million RMB, with a year-on-year decrease of 13.81%, followed by growth of 14.96% in 2026 and 14.06% in 2027 [5][6] - The company's return on equity (ROE) is expected to be 17.90% in 2025, decreasing from 25.27% in 2024 [5][7] - The price-to-earnings (P/E) ratio is projected to be 16.82 in 2025, indicating a favorable valuation compared to historical levels [5]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][10]. Core Insights - The company reported a revenue of 7.52 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.8%. EBITDA increased by 23.3% to 2.75 billion yuan, and net profit attributable to shareholders rose by 27.0% to 1.89 billion yuan [4][5]. Company Overview - Latest closing price: HKD 13.14 - Total shares: 1.973 billion - Total market capitalization: HKD 29.023 billion - 52-week high/low: HKD 17.774 / HKD 9.309 - Debt-to-asset ratio: 46.96% - Price-to-earnings ratio: 8.3 [3]. Financial Performance - The intermediate products segment saw a revenue decline of 23.1% to 1.01 billion yuan, with a profit margin of 27.5%, down by 7.2 percentage points. The active pharmaceutical ingredients segment's revenue fell by 27.0% to 2.53 billion yuan, with a profit margin of 27.5%, down by 4.9 percentage points. The formulation segment's revenue increased by 6.1% to 2.54 billion yuan, with a profit margin of 6.1%, down by 4.0 percentage points. Licensing income was 1.43 billion yuan, primarily from the UBT251 licensing fee [5][6]. - The insulin formulation business showed significant growth, with revenue reaching 960 million yuan, a 74.5% increase. The second-generation insulin revenue was 460 million yuan, up 110.2%, while the revenue from glargine insulin and aspart insulin increased by 33.7% and 74.0%, respectively [6]. Research and Development - The company invested 550 million yuan in R&D, a 14.9% increase. The GLP-1/GIP/GCG triple-target new drug UBT251 has been licensed to Novo Nordisk, with ongoing clinical trials for weight loss and diabetes indications. The company expects to enter a harvest period starting in 2026, with six new products or indications anticipated for approval in 2026 and 2027 [7][8]. Financial Forecast - Projected revenues for 2025, 2026, and 2027 are 13.42 billion yuan, 12.65 billion yuan, and 13.84 billion yuan, respectively, with year-on-year growth rates of -2.5%, -5.7%, and 9.4%. Net profit attributable to shareholders is forecasted at 2.36 billion yuan, 2.02 billion yuan, and 2.41 billion yuan for the same years, with corresponding growth rates of -11.4%, -14.2%, and 19.4% [12][8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [2][6]. Core Insights - The company reported a revenue of 29.39 billion RMB for the first three quarters of 2025, reflecting a year-over-year decline of 4.9%. However, the net profit attributable to the parent company was 2.52 billion RMB, showing a year-over-year increase of 25.5% [6]. - The company has faced challenges due to centralized drug procurement affecting revenue from generic drugs, but innovative products have continued to grow, with innovative drug revenue exceeding 6.7 billion RMB, a year-over-year increase of 18.1% [6]. - The gross margin for Q3 was 48.4%, a slight increase of 0.3 percentage points year-over-year, driven by a higher proportion of high-margin innovative drug products [6]. - The report anticipates net profits for 2025-2027 to be 3.32 billion RMB, 3.96 billion RMB, and 4.77 billion RMB, respectively, with year-over-year growth rates of 19.9%, 19.4%, and 20.4% [6][7]. Financial Summary - The company’s projected net profit for 2025 is 3.32 billion RMB, with an EPS of 1.24 RMB, and a corresponding H-share P/E ratio of 17.21 [7]. - Revenue is expected to reach 44.87 billion RMB in 2025, with a slight increase in operating profit to 5.04 billion RMB [9]. - The company’s cash flow from operating activities is projected to be 4.32 billion RMB in 2025, indicating a positive cash flow trend [10].

Investment Rating - The report maintains a strong buy rating for Li Ning (02331.HK) with a target price not specified [2][5] Core Views - In Q3 2025, the company's overall revenue faced pressure due to warmer weather, resulting in a year-on-year decline in total revenue in the mid-single digits. Despite deeper discounts, inventory remains controllable, and the company will continue to optimize channel structure while investing in Olympic marketing and product innovation. Management maintains guidance for flat revenue and high single-digit net profit margin for 2025 [1][5] - The projected net profit for 2025-2027 is estimated at 2.4 billion, 2.71 billion, and 2.96 billion yuan, with year-on-year growth rates of -21%, 13%, and 9% respectively. The current stock price corresponds to a PE of 17X for 2025 and 15X for 2026 [1][5] Summary by Sections Revenue Performance - In Q3 2025, total revenue declined in the mid-single digits year-on-year, with a weakening trend observed month by month from July to September. Offline channels saw a high single-digit decline, while online channels experienced high single-digit growth [5][6] - The overall discount level increased in Q3 2025, with inventory levels remaining healthy and controllable, expected to be within 4-5 months by year-end [5][6] Store Expansion and Product Innovation - The number of main brand stores increased to 6,132 by the end of Q3 2025, with a net addition of 33 stores compared to the previous quarter. The company continues to push for product innovation, with new launches planned in running, basketball, and outdoor categories [5][6] Marketing and Brand Strategy - The company is actively promoting its brand through Olympic marketing initiatives, including the release of the 2026 Milan Winter Olympics Chinese sports delegation award equipment and collaborations in skiing events [5][6] Financial Projections - Revenue projections for 2025-2027 are 28.74 billion, 30.29 billion, and 31.87 billion yuan, with growth rates of 0%, 5%, and 5% respectively. Net profit projections are 2.4 billion, 2.71 billion, and 2.96 billion yuan, with growth rates of -21%, 13%, and 9% respectively [6][9]